<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02317042</url>
  </required_header>
  <id_info>
    <org_study_id>MA250814</org_study_id>
    <nct_id>NCT02317042</nct_id>
  </id_info>
  <brief_title>Juno Perth Clinical Trial</brief_title>
  <official_title>The Evaluation of the Sleep-Breathing Treatment Algorithm: AutoEPAP iVAPS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ResMed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sir Charles Gairdner Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Western Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ResMed</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the efficacy of a new therapy (Automatic Expiratory Positive Airway&#xD;
      Pressure with intelligent Volume Assured Pressure Support (AutoEPAP iVAPS)) designed to treat&#xD;
      respiratory insufficiency, respiratory failure and/or nocturnal hypoventilation with upper&#xD;
      airway obstruction. The study will be performed in two phases: In a sleep unit and in the&#xD;
      home environment. The new therapy will be compared against two existing ventilator therapies:&#xD;
      &quot;Spontaneous Timed (ST) mode&quot; and &quot;Intelligent Volume Assured Pressure Support (iVAPS)&quot;.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I: AutoEPAP iVAPS will be compared against two existing ventilator therapies:&#xD;
      &quot;Spontaneous Timed (ST) mode&quot; and &quot;Intelligent Volume Assured Pressure Support (Fixed EPAP&#xD;
      iVAPS)&quot; in current NIV users with respiratory insufficiency and /or respiratory failure due&#xD;
      to Chronic Obstructive Pulmonary Disease (COPD),Obesity Hypoventilation Syndrome (OHS) or&#xD;
      Neuromuscular Disease (NMD). Patients will spend a total of 3 nights in the sleep laboratory&#xD;
      in the three modes described above. The apnoea-hypopnoea index will be the primary outcome&#xD;
      measure.&#xD;
&#xD;
      Phase II: AutoEPAP iVAPS will be compared to ST mode over a period of 7 nights in the&#xD;
      patients' home. The mean EPAP setting of each device will be the primary outcome measure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Phase II not initiated for commercial reasons (no safety related issues)&#xD;
  </why_stopped>
  <start_date type="Actual">May 29, 2015</start_date>
  <completion_date type="Actual">November 29, 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apnoea-Hypopnoea Index (AHI)</measure>
    <time_frame>1 night</time_frame>
    <description>The number of apneas and hypopnoeas per hour of sleep measured using AutoEPAP iVAPS versus Fixed EPAP iVAPS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygen Desaturation Index</measure>
    <time_frame>1 night</time_frame>
    <description>Number of oxygen desaturations per hour of sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Oxygen Saturation</measure>
    <time_frame>1 night</time_frame>
    <description>Mean oxygen saturation recorded in the total sleep time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent Below 90% Oxygen Saturation</measure>
    <time_frame>1 night</time_frame>
    <description>Time in minutes that the oxygen saturation was below 90%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Transcutaneous Carbon Dioxide (PtcCo2)</measure>
    <time_frame>1 night</time_frame>
    <description>Transcutaneous Carbon Dioxide measurement (TcCO2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Duration</measure>
    <time_frame>1 Night</time_frame>
    <description>Time spent asleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Efficacy</measure>
    <time_frame>1 Night</time_frame>
    <description>Sleep time divided by total time available for sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Latency-Wake After Sleep Onset Time</measure>
    <time_frame>1 Night</time_frame>
    <description>Time awake in minutes after initial sleep onset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Sleep Time Spent in Each Sleep Stage</measure>
    <time_frame>1 Night</time_frame>
    <description>Percentage of total sleep time spent in each sleep stage (ie. N1, N2, N3 and REM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Respiratory Event Related Arousals/ Hour</measure>
    <time_frame>1 Night</time_frame>
    <description>Total number of respiratory event related arousals/hr over the entire sleep period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Spontaneous Arousals/Hour</measure>
    <time_frame>1 Night</time_frame>
    <description>Number of spontaneous arousals/hr occurring over the entire total sleep time</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Respiratory Insufficiency</condition>
  <condition>Obesity Hypoventilation Syndrome</condition>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <condition>Neuromuscular Disease</condition>
  <condition>Upper Airway Obstruction</condition>
  <arm_group>
    <arm_group_label>Standard ST Mode</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants underwent the first PSG study (Titration Night 1) on ST Mode ( prior to going on AutoEPAP iVAPS or Fixed EPAP iVAPS) whilst receiving their standard NIV therapy through the clinical trial device &quot;Juno&quot;. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AutoEPAP iVAPS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants underwent a PSG study on the AutoEPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed EPAP iVAPS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants underwent a PSG study on the Fixed EPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Juno</intervention_name>
    <description>Juno device set to ST mode with participant's current therapy settings.</description>
    <arm_group_label>Standard ST Mode</arm_group_label>
    <other_name>ResMed &quot;Juno&quot; Device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Juno</intervention_name>
    <description>Juno device set to AutoEPAP iVAPS mode.</description>
    <arm_group_label>AutoEPAP iVAPS</arm_group_label>
    <other_name>ResMed &quot;Juno&quot; Device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Juno</intervention_name>
    <description>Juno device set to Fixed EPAP iVAPS mode.</description>
    <arm_group_label>Fixed EPAP iVAPS</arm_group_label>
    <other_name>ResMed &quot;Juno&quot; Device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Subject has ability to provide written informed consent&#xD;
&#xD;
          -  Subject aged ≥18 years old&#xD;
&#xD;
          -  Subject has a diagnosis of COPD, OHS or NMD with sleep hypoventilation (historical&#xD;
             PtCO2 increase overnight ≥ 10mmHg) and/or daytime hypercapnia (&gt;45 mmHg)&#xD;
&#xD;
          -  Subject is currently using non-invasive ventilation for ≥ 3 months&#xD;
&#xD;
          -  Subject with an AHI ≥ 5 hr. (as documented in diagnostic or pressure determination&#xD;
             sleep study report)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Subjects not compliant on NIV (ie. &lt; 4 hr/night)&#xD;
&#xD;
          -  Subjects with severe asthma&#xD;
&#xD;
          -  Subjects who are pregnant&#xD;
&#xD;
          -  Subjects on oxygen therapy (ie. &gt;4 L/min)&#xD;
&#xD;
          -  Subjects with a tracheostomy&#xD;
&#xD;
          -  Subjects who are acutely ill, medically complicated or who are medically unstable&#xD;
&#xD;
          -  Subjects in whom PAP therapy is otherwise medically contraindicated&#xD;
&#xD;
          -  Subjects who have had surgery of the upper airway, nose, sinus, or middle ear within&#xD;
             the previous 90 days&#xD;
&#xD;
          -  Subjects with untreated, non-OSA sleep disorders, including but not limited to;&#xD;
             insomnia, periodic limb movement syndrome, or restless legs syndrome.&#xD;
&#xD;
          -  Subjects who require ventilatory support during wakefulness&#xD;
&#xD;
          -  Subjects with the following pre-existing conditions: severe bullous lung disease,&#xD;
             recurrent pneumothorax or pneumomediastinum, low blood pressure, cerebrospinal fluid&#xD;
             leak, recent cranial surgery or trauma.&#xD;
&#xD;
          -  Subjects with severe developmental delay and who will not be able to follow tasks as&#xD;
             instructed in the protocol.&#xD;
&#xD;
          -  Subjects who the investigator believes are unsuitable for inclusion because either:&#xD;
&#xD;
               -  they do not comprehend English&#xD;
&#xD;
               -  they are unable or unwilling to provide written informed consent&#xD;
&#xD;
               -  they are physically unable to comply with the protocol&#xD;
&#xD;
               -  they are unsuitable to participate in the trial for any other reason in the&#xD;
                  opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Western Australia</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 8, 2014</study_first_submitted>
  <study_first_submitted_qc>December 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2014</study_first_posted>
  <results_first_submitted>May 14, 2017</results_first_submitted>
  <results_first_submitted_qc>May 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 8, 2021</results_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Hypoventilation</mesh_term>
    <mesh_term>Airway Obstruction</mesh_term>
    <mesh_term>Obesity Hypoventilation Syndrome</mesh_term>
    <mesh_term>Neuromuscular Diseases</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>An overnight PSG retitration was performed by experienced sleep technologists to ensure current EPAP &amp; other device settings were optimal. Titration took place with the device in ST mode with the patient's usual therapy setup. If the device settings were not optimal or if other problems such as patient-device dysynchrony, then the ventilator settings were adjusted by the sleep technologist based on current guidelines. Retitration studies were reviewed by at least 2 experienced sleep physicians.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard ST Mode -&gt; AutoEPAP iVAPS -&gt; Fixed EPAP iVAPS</title>
          <description>Night 1 Participants underwent the first PSG study on ST Mode receiving their standard NIV therapy through the clinical trial device &quot;Juno&quot;. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy.&#xD;
Night 2 Participants underwent a PSG study on the AutoEPAP iVAPS mode Night 3 Participants underwent a PSG study on the Fixed EPAP iVAPS mode</description>
        </group>
        <group group_id="P2">
          <title>Standard ST Mode -&gt; FixedEPAP iVAPS -&gt; AutoEPAP iVAPS Mode</title>
          <description>Night 1 Participants underwent the first PSG study on ST Mode receiving their standard NIV therapy through the clinical trial device &quot;Juno&quot;. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy.&#xD;
Night 2 Participants underwent a PSG study on the FixedEPAP iVAPS mode Night 3 Participants underwent a PSG study on the AutoEPAP iVAPS mode</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Participant Baseline</title>
          <description>Participant's meeting the eligibility criteria had their baseline information collected at their Visit 1.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Apnoea-Hypopnoea Index (AHI)</title>
        <description>The number of apneas and hypopnoeas per hour of sleep measured using AutoEPAP iVAPS versus Fixed EPAP iVAPS</description>
        <time_frame>1 night</time_frame>
        <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard ST Mode</title>
            <description>Participants underwent the first PSG study (Titration Night 1) on ST Mode whilst receiving their standard NIV therapy through the clinical trial device &quot;Juno&quot;. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy.</description>
          </group>
          <group group_id="O2">
            <title>AutoEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the AutoEPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
          <group group_id="O3">
            <title>FixedEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the Fixed EPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
        </group_list>
        <measure>
          <title>Apnoea-Hypopnoea Index (AHI)</title>
          <description>The number of apneas and hypopnoeas per hour of sleep measured using AutoEPAP iVAPS versus Fixed EPAP iVAPS</description>
          <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
          <units>events/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.87" spread="6.19"/>
                    <measurement group_id="O2" value="3.57" spread="3.76"/>
                    <measurement group_id="O3" value="4.09" spread="5.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygen Desaturation Index</title>
        <description>Number of oxygen desaturations per hour of sleep</description>
        <time_frame>1 night</time_frame>
        <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard ST Mode</title>
            <description>Participants underwent the first PSG study (Titration Night 1) on ST Mode whilst receiving their standard NIV therapy through the clinical trial device &quot;Juno&quot;. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy.</description>
          </group>
          <group group_id="O2">
            <title>AutoEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the AutoEPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
          <group group_id="O3">
            <title>FixedEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the Fixed EPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygen Desaturation Index</title>
          <description>Number of oxygen desaturations per hour of sleep</description>
          <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
          <units>events/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.06" spread="6.18"/>
                    <measurement group_id="O2" value="4.45" spread="4.15"/>
                    <measurement group_id="O3" value="5.70" spread="8.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Oxygen Saturation</title>
        <description>Mean oxygen saturation recorded in the total sleep time</description>
        <time_frame>1 night</time_frame>
        <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard ST Mode</title>
            <description>Participants underwent the first PSG study (Titration Night 1) on ST Mode whilst receiving their standard NIV therapy through the clinical trial device &quot;Juno&quot;. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy.</description>
          </group>
          <group group_id="O2">
            <title>AutoEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the AutoEPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
          <group group_id="O3">
            <title>FixedEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the Fixed EPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Oxygen Saturation</title>
          <description>Mean oxygen saturation recorded in the total sleep time</description>
          <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
          <units>percentage of oxygen saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.99" spread="1.97"/>
                    <measurement group_id="O2" value="94.01" spread="1.89"/>
                    <measurement group_id="O3" value="94.33" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent Below 90% Oxygen Saturation</title>
        <description>Time in minutes that the oxygen saturation was below 90%</description>
        <time_frame>1 night</time_frame>
        <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard ST Mode</title>
            <description>Participants underwent the first PSG study (Titration Night 1) on ST Mode whilst receiving their standard NIV therapy through the clinical trial device &quot;Juno&quot;. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy.</description>
          </group>
          <group group_id="O2">
            <title>AutoEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the AutoEPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
          <group group_id="O3">
            <title>FixedEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the Fixed EPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Spent Below 90% Oxygen Saturation</title>
          <description>Time in minutes that the oxygen saturation was below 90%</description>
          <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.26" spread="78.18"/>
                    <measurement group_id="O2" value="37.03" spread="87.75"/>
                    <measurement group_id="O3" value="34.31" spread="100.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Transcutaneous Carbon Dioxide (PtcCo2)</title>
        <description>Transcutaneous Carbon Dioxide measurement (TcCO2)</description>
        <time_frame>1 night</time_frame>
        <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard ST Mode</title>
            <description>Participants underwent the first PSG study (Titration Night 1) on ST Mode whilst receiving their standard NIV therapy through the clinical trial device &quot;Juno&quot;. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy.</description>
          </group>
          <group group_id="O2">
            <title>AutoEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the AutoEPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
          <group group_id="O3">
            <title>FixedEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the Fixed EPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Transcutaneous Carbon Dioxide (PtcCo2)</title>
          <description>Transcutaneous Carbon Dioxide measurement (TcCO2)</description>
          <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.73" spread="6.10"/>
                    <measurement group_id="O2" value="47.44" spread="5.04"/>
                    <measurement group_id="O3" value="46.78" spread="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Duration</title>
        <description>Time spent asleep</description>
        <time_frame>1 Night</time_frame>
        <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard ST Mode</title>
            <description>Participants underwent the first PSG study (Titration Night 1) on ST Mode whilst receiving their standard NIV therapy through the clinical trial device &quot;Juno&quot;. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy.</description>
          </group>
          <group group_id="O2">
            <title>AutoEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the AutoEPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
          <group group_id="O3">
            <title>FixedEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the Fixed EPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Duration</title>
          <description>Time spent asleep</description>
          <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333.4" spread="86.06"/>
                    <measurement group_id="O2" value="331.7" spread="109.08"/>
                    <measurement group_id="O3" value="340.9" spread="110.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Efficacy</title>
        <description>Sleep time divided by total time available for sleep</description>
        <time_frame>1 Night</time_frame>
        <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard ST Mode</title>
            <description>Participants underwent the first PSG study (Titration Night 1) on ST Mode whilst receiving their standard NIV therapy through the clinical trial device &quot;Juno&quot;. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy.</description>
          </group>
          <group group_id="O2">
            <title>AutoEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the AutoEPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
          <group group_id="O3">
            <title>FixedEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the Fixed EPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Efficacy</title>
          <description>Sleep time divided by total time available for sleep</description>
          <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
          <units>percentage of total recorded time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" spread="15"/>
                    <measurement group_id="O2" value="66" spread="15"/>
                    <measurement group_id="O3" value="66" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Latency-Wake After Sleep Onset Time</title>
        <description>Time awake in minutes after initial sleep onset</description>
        <time_frame>1 Night</time_frame>
        <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard ST Mode</title>
            <description>Participants underwent the first PSG study (Titration Night 1) on ST Mode whilst receiving their standard NIV therapy through the clinical trial device &quot;Juno&quot;. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy.</description>
          </group>
          <group group_id="O2">
            <title>AutoEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the AutoEPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
          <group group_id="O3">
            <title>FixedEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the Fixed EPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Latency-Wake After Sleep Onset Time</title>
          <description>Time awake in minutes after initial sleep onset</description>
          <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.56" spread="17.41"/>
                    <measurement group_id="O2" value="29.98" spread="43.19"/>
                    <measurement group_id="O3" value="28.12" spread="29.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Sleep Time Spent in Each Sleep Stage</title>
        <description>Percentage of total sleep time spent in each sleep stage (ie. N1, N2, N3 and REM)</description>
        <time_frame>1 Night</time_frame>
        <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard ST Mode</title>
            <description>Participants underwent the first PSG study (Titration Night 1) on ST Mode whilst receiving their standard NIV therapy through the clinical trial device &quot;Juno&quot;. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy.</description>
          </group>
          <group group_id="O2">
            <title>AutoEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the AutoEPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
          <group group_id="O3">
            <title>FixedEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the Fixed EPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Sleep Time Spent in Each Sleep Stage</title>
          <description>Percentage of total sleep time spent in each sleep stage (ie. N1, N2, N3 and REM)</description>
          <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time spent in N1 Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.68" spread="33.88"/>
                    <measurement group_id="O2" value="76.62" spread="45.18"/>
                    <measurement group_id="O3" value="82.08" spread="46.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time spent in N2 Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186.9" spread="67.14"/>
                    <measurement group_id="O2" value="172.3" spread="74.08"/>
                    <measurement group_id="O3" value="174.9" spread="85.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time spent in N3 Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.36" spread="26.43"/>
                    <measurement group_id="O2" value="37.38" spread="31.26"/>
                    <measurement group_id="O3" value="29.98" spread="24.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time spent in REM Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.04" spread="26.36"/>
                    <measurement group_id="O2" value="45.30" spread="24.99"/>
                    <measurement group_id="O3" value="54.00" spread="44.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Respiratory Event Related Arousals/ Hour</title>
        <description>Total number of respiratory event related arousals/hr over the entire sleep period</description>
        <time_frame>1 Night</time_frame>
        <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard ST Mode</title>
            <description>Participants underwent the first PSG study (Titration Night 1) on ST Mode whilst receiving their standard NIV therapy through the clinical trial device &quot;Juno&quot;. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy.</description>
          </group>
          <group group_id="O2">
            <title>AutoEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the AutoEPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
          <group group_id="O3">
            <title>FixedEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the Fixed EPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Respiratory Event Related Arousals/ Hour</title>
          <description>Total number of respiratory event related arousals/hr over the entire sleep period</description>
          <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
          <units>arousals/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" spread="5.85"/>
                    <measurement group_id="O2" value="5.67" spread="4.14"/>
                    <measurement group_id="O3" value="6.54" spread="7.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Spontaneous Arousals/Hour</title>
        <description>Number of spontaneous arousals/hr occurring over the entire total sleep time</description>
        <time_frame>1 Night</time_frame>
        <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard ST Mode</title>
            <description>Participants underwent the first PSG study (Titration Night 1) on ST Mode whilst receiving their standard NIV therapy through the clinical trial device &quot;Juno&quot;. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy.</description>
          </group>
          <group group_id="O2">
            <title>AutoEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the AutoEPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
          <group group_id="O3">
            <title>FixedEPAP iVAPS</title>
            <description>Participants underwent a PSG study on the Fixed EPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.&#xD;
Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Spontaneous Arousals/Hour</title>
          <description>Number of spontaneous arousals/hr occurring over the entire total sleep time</description>
          <population>Participants included in the study were those with a documented diagnosis of respiratory insufficiency and /or respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS) and Neuromuscular Disease (NMD).</population>
          <units>arousals/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.41" spread="21.09"/>
                    <measurement group_id="O2" value="29.21" spread="18.16"/>
                    <measurement group_id="O3" value="31.92" spread="23.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard ST Mode</title>
          <description>Standard ST mode.</description>
        </group>
        <group group_id="E2">
          <title>AutoEPAP iVAPS</title>
          <description>AutoEPAP iVAPS.</description>
        </group>
        <group group_id="E3">
          <title>FixedEPAP iVAPS</title>
          <description>FixedEPAP iVAPS.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple Falls</sub_title>
                <description>Subject admitted to hospital following multiple falls which occurred after Titration Night 1. A rib fracture as a result of the SAE was noted at a later date. SAE and secondary event not related to study device or disease targeted by the trial.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>AEROPHAGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>MILD CHEST INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SORE BACK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SKIN ABRASION TO CHIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor has the right to&#xD;
review&#xD;
provide comments (site is not bound to follow them)&#xD;
request delay of publication for no more than 120 days to allow for securing of IP&#xD;
request the removal of specified confidential information&#xD;
within 40 days of the proposed publication being released to those not bound by confidentiality obligations.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof Nigel McArdle &amp; Prof Peter Eastwood</name_or_title>
      <organization>University of Western Australia</organization>
      <phone>+61 8 9346 1706</phone>
      <email>peter.eastwood@health.wa.gov.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

